We’re pleased to announce that KAC Co., Ltd. is now the official partner supporting the promotion and delivery of EBiSC iPSC lines in Japan.
KAC brings extensive experience supplying cell lines, primary cells, culture media, sera and research reagents to laboratories across Japan. Through this collaboration, researchers will benefit from simplified local access, improved logistics and dedicated support when ordering from the EBiSC catalogue of 1000 high-quality iPSC lines covering more than 45 disease areas.
This partnership strengthens EBiSC’s global network and supports our mission to make well-characterised iPSC resources accessible to researchers worldwide.
🧬 Explore EBiSC’s iPSC collection: www.ebisc.org
📩 Contact KAC: https://lnkd.in/eXZi8XP8
🌐 www.kacnet.co.jp
Tag: EBiSC
Isogenic LRRK2 iPSC lines now available via EBiSC!
Understanding the molecular drivers of Parkinson’s disease is essential for developing effective treatments and the LRRK2 gene remains one of the most significant contributors to both inherited and sporadic forms of the condition.
To investigate this, researchers led by Dr Sally Cowley at the Oxford Parkinson’s Disease Centre have shared a set of LRRK2 gene-edited iPSC lines, including isogenic knockouts and disease-associated variants. These models were generated from high-quality parental lines originally developed through the StemBANCC collaboration, demonstrating the continued impact of large, multi-partner initiatives in building resources which can be shared and used by all researchers.
These iPSC lines are fully quality-controlled and come with comprehensive metadata, enabling robust and reproducible studies of LRRK2 function, cellular pathology, and therapeutic targets.
🔬 Explore these LRRK2 iPSC lines in the EBiSC catalogue: https://ebisc.org/search?q=&hpscreg-genes=%5B%22LRRK2%22%5D&product-status=%5B%5D&gene-edited=true
Big news for biomedical researchers in Australia and New Zealand!
We’re excited to announce that CellBank Australia is now the official distributor of the EBiSC stem cell collection for Australia and New Zealand — making it easier than ever for researchers across Oceania to access 950+ high-quality iPSC lines covering more than 45 disease areas, including cardiovascular, neurological, and metabolic disorders.
This partnership expands EBiSC’s global reach, ensuring that our validated iPSC lines and pre-differentiated cells are available to support research in disease modelling, drug discovery, and regenerative medicine across the region.
Operated by the Children’s Medical Research Institute (CMRI), CellBank brings 18+ years of expertise in authenticated cell lines and quality control services. The collaboration is further strengthened by CMRI’s Stem Cell and Organoid Facility, advancing 3D organoid models and translational research.
🌐 https://www.cellbankaustralia.com/cell-lines-for-distribution/
New publication: How FAIR is metadata for human pluripotent stem cells?
EBiSC has been featured in the recent Stem Cell Reports publication, “How FAIR is metadata for human pluripotent stem cells?”, which highlights the importance of applying FAIR principles — Findable, Accessible, Interoperable, and Reusable — to stem cell metadata.
At EBiSC, we share this commitment. As a centralised iPSC repository, we work closely with partners such as hPSCreg to ensure that iPSC line and donor data are standardised, traceable, and accessible to the global research community. Ensuring that iPSC resources are not only available but also discoverable and reusable is essential for accelerating progress in disease modelling, drug discovery, and regenerative medicine.
Explore the paper here:
🔗 https://www.cell.com/stem-cell-reports/fulltext/S2213-6711(25)00248-6
Enabling a Patient-Derived Resource for Angelman Syndrome Research at EBiSC
Angelman syndrome is rare (about 1 in 15,000), but it’s one of the most actionable neurogenetic conditions. The Foundation for Angelman Syndrome Therapeutics (FAST), the largest non-governmental funder of Angelman syndrome research, is turning that potential into tools that labs can use now.
With Yale University and EBiSC, FAST has funded and built a curated panel of Angelman syndrome iPSC lines that reflect the real genetics seen in clinic: full range of AS genotypes, deletion, point mutations, UPD, ICD, and relevant controls. These lines are available for pre-order via EBiSC so teams can move faster on target validation, screening, and mechanism studies.
Explore and request lines: https://ebisc.org/search?q=Yui&disease-super-classes=[]
Interested in working with FAST? Explore their research programs and funding opportunities at www.cureangelman.org/research.
#CureAngelman #AngelmanSyndrome #RareDisease #research #EBiSC
New iPSC Resource Available for Alzheimer’s Research via EBiSC!
A new study just published in Stem Cell Reports (PMID 40614728) introduces the IPMAR Resource funded by the UK Dementia Research Institute (UKDRI): a collection of human induced pluripotent stem cell (iPSC) lines designed to reflect high and low polygenic risk for Alzheimer’s disease. This comprehensive panel captures extremes of genetic predisposition across early- and late-onset forms of AD, with over a high number of donor-derived lines representing diverse clinical and genetic profiles pubmed.ncbi.nlm.nih.gov+6ukdri.ac.uk+6ebisc.org+6.
Key highlights:
- Models span high- and low-risk individuals based on global and complement‑pathway AD polygenic risk scores
- All lines come with linked clinical, longitudinal, and genetic data
🎉 The great news? The iPSC lines are now available through EBiSC, offering a vital tool for disease modelling and further research.
➡️ Learn more and secure access via the EBiSC catalogue. https://ebisc.org/collections/ipmar_alzheimers_disease
📩 For inquiries or collaboration opportunities, feel free to get in touch.
Congenital Muscular Dystrophy collection now available via EBiSC.
Skeletal muscle laminopathies are rare genetic disorders caused by pathogenic mutations in the LMNA gene, leading to progressive muscle weakness and other severe symptoms. This study by researchers at UCL demonstrates the use of iPSCs carrying LMNA mutations to model these conditions, offering valuable insights into disease mechanisms and therapeutic opportunities.
We’re pleased to share that CureCMD have now made the iPSC lines featured in this research available through EBiSC. These lines provide an essential tool for researchers studying laminopathies and advancing treatments for these challenging disorders.
Access the collection and learn more here. Let’s drive innovation in skeletal muscle disease research!
https://ebisc.org/search?q=CMDi
#Laminopathies #SkeletalMuscleResearch #iPSC #EBiSC #Genetics #DiseaseModeling #RareDiseases
Focal Segmental Glomerulosclerosis (FSGS) iPSCs and clinical data
We’re happy to share that the iPSC lines from the study “Generation of 20 Human Induced Pluripotent Stem Cell Lines from Patients with Focal Segmental Glomerulosclerosis (FSGS)” are available through EBiSC!
These iPSC lines, derived from patients with FSGS, provide a valuable resource for studying kidney disease mechanisms and testing potential therapies. Detailed clinical data is available upon request for researchers looking to deepen their understanding of FSGS.
Explore the iPSC lines and access data via EBiSC here to drive forward your nephrology research.
#FSGS #iPSC #KidneyResearch #EBiSC #GeneticResearch #DiseaseModeling #Nephrology #RegenerativeMedicine
Exciting Partnership Announcement: EBISC Teams Up with Sampled to Support USA Shipments for iPSC Resources
Exciting Partnership Announcement: EBISC Teams Up with Sampled to Support USA Shipments for iPSC Resources
EBISC (European Bank for Induced Pluripotent Stem Cells) has teamed up with Sampled, a global leader in biorepository and laboratory services, to enhance distribution capabilities for American researchers.
What This Means for Researchers
For American researchers, this partnership will simplify the procurement process for iPSC resources, allowing them to focus more on their research objectives and less on logistics. The enhanced local distribution ensures that high-quality samples can be efficiently shipped, helping to save time and reducing the cost of shipping.
Looking Ahead
As this exciting collaboration unfolds, we are confident that it will significantly improve the availability and accessibility of iPSC resources for researchers in the United States. This partnership represents a key step toward creating a more connected and efficient global research ecosystem.
Stay tuned for further updates on how EBISC and Sampled are working together to support scientific discovery and innovation. We look forward to seeing the incredible advancements that will come from this new chapter in research collaboration.
For more information on how this partnership will benefit your research, visit EBISC and Sampled.
EBiSC – European Bank for Induced pluripotent Stem Cells
Sampled – Any Sample, Every Answer.
New publication on EBiSC-NEUR1 neurons!
We’re thrilled to see the paper “Measurements of Neurite Extension and Nucleokinesis in an iPSC-Derived Model System Following Microtubule Perturbation” published, showcasing the power of EBiSC iPSC-derived neurons.
This study highlights how iPSC technology can be used to model and measure key cellular processes like neurite extension and nucleokinesis, offering valuable insights into neurodevelopmental diseases. It’s exciting to see how EBiSC-generated iPSC lines are contributing to cutting-edge research that deepens our understanding of cellular dynamics and disease mechanisms.
https://pubmed.ncbi.nlm.nih.gov/39602292
#iPSC #Neurodegeneration #Neuroscience #EBiSC #DiseaseModeling #StemCellResearch #Neurodevelopment